Once again I am telling you that those are drugs many anavex trial patients WILL be on for at least 3 months in this trial and WILL be in the placebo group. My link suggests a significant percentage of those placebo patients will actually still be above baseline based on a 734 patient data collection of a longitudinal study going out 36 months. Therefore it is irresponsible posting that ZERO placebo patients will be above baseline at the conclusion the current trial Imo.
There will be patients above baseline in both the placebo and treatment group just as it was for the 3 drugs in the study I linked. Its to be expected but some seem to think any patients above baseline has never been seen before. Hardly the case.
Market Data 
Markets 
AI
